BioE, Inc. is a biomedical company that provides enabling, high-quality human stem cells for drug discovery and therapeutic research. Dan Collins, Ph.D., executive vice president and chief scientific officer for BioE, with leading physicians and researchers from Morgan Stanley Children’s Hospital of NewYork-Presbyterian and Columbia University Medical Center reported on BioE’s Multi-Lineage Progenitor Cells (MLPCs) as a cord blood stem cell with potential for therapeutic and cell regeneration applications. Specifically, the researchers cite the MLPC’s controlled and extensive differentiation capabilities, genetic stability and lack of teratoma formation, and ability to develop pure clonal cell lines as key characteristics that define the stem cell’s high utility compared to embryonic stem cells and adult-source stem cells.
“BioE's MLPC stem cell shows great promise as a critical cord blood stem cell that in the future could be utilized to regenerate a variety of tissues including cardiac, skin, nervous, pancreatic (insulin producing) among others,” said senior author Mitchell S. Cairo, M.D., chief, Blood & Marrow Transplantation at Morgan Stanley Children's Hospital and professor of pediatrics, medicine, and pathology at Columbia University College of Physicians and Surgeons. “As stem cell research continues to advance on many fronts, cord blood stem cells - including the MLPC - likely will provide researchers a viable source of cells to help repair numerous tissues within the body in the near term. Compared to embryonic and adult stem cells, cord blood stem cells are widely available, and their immaturity and flexibility should produce larger quantities of homogeneous tissues or cells for transplantation and help minimize rejection of generated tissue when transplanted into a mismatched host.”
While cord blood stem cells were once considered functionally limited, the review’s authors discuss a voluminous body of research demonstrating their ability to differentiate into non-blood-related cells and tissue lineages. For example, research shows the cord blood-derived MLPC stem cell has the ability to turn into cells representative of the three different embryonic germinal layers, including liver and pancreatic precursor cells, terminally differentiated liver cells, lung cells, fat cells, cartilage cells, bone cells, skeletal muscle, blood vessels, neural stem cells, and nerve cells.
“The MLPC is an attractive cord blood stem cell for many researchers due to its significant differentiation capabilities, easy accessibility, and ability to maintain genetic stability through 80 doublings,” Dr. Collins said. “The clonally derived cells can be expanded into therapeutically relevant numbers of cells, thus providing a pure population of identically behaving cells.”
“We are pleased to see the MLPC recognized as a cord blood stem cell at the forefront of stem cell research,” Dr. Collins said. “While further and continued research is required, we are hopeful that the MLPC has the characteristics and functionality needed to one day help impact medicine and improve patient care.”
Along with describing research involving the MLPC stem cell, the Experimental Hematology paper summarizes cord blood stem cell benefits and additional “in vitro and in vivo studies examining umbilical cord blood stem cells and their potential use for therapeutic application for non-hematopoietic tissue and cell regeneration.” Experimental Hematology is the official journal of the Society for Hematology and Stem Cells.
Illustration: BioE’s Multi-Lineage Progenitor Cells, BioE.
BioE News Release (12/18/07)
Yahoo! Finance (12/18/07)
Greenville Spartanburg Anderson Technology Council (12/18/07)
Business Wire (12/18/07)
Genetic Engineering & Biotechnology News (12/18/07)
Medical News Today (12/20/07)
Stem Cells.Net (12/24/07)
Abstract (Experimental Hematology, Volume 35, Issue 12, December 2007, Pages 1753-1765)